Background: Alzheimer's disease (AD), a common protein misfolding progressive neurodegenerative
disorder, is one of the most common forms of dementia. Amyloid precursor protein (APP)
derived amyloid-β (Aβ) protein accumulate into interneuronal spaces and plays a crucial role in the disease
progression and its pathology. The aggregated Aβ exerts its neurotoxic effects by inducing apoptosis
and oxidative damage in neuronal cells.
Objectives: We have investigated the effects of a synthesized Pro-Drug peptide (PDp) on Aβ1-40 induced
cytotoxicity in human neuroblastoma SH-SY5Y cells, represents one of the most effective strategies
in combating human AD.
Methods: Cells were treated with Aβ1-40 to induce cytotoxicity in the experimental model of AD to
screen the inhibitory effect of PDp. Assays for cell viability, reactive oxygen species (ROS) generation,
levels of intracellular free Ca2+ and expression of key apoptotic proteins were assessed by Western Blotting.
Results: Our results showed that Aβ1-40 induces for 24h caused reduce cell viability, imbalance in Ca2+
homeostasis and increase in neuronal apoptosis in vitro. Treatment with PDp could effectively ameliorated
Aβ1-40 induced neurotoxicity and attenuates ROS generation that mediates apoptotic signaling
through Bcl-2, Bax, Caspase-3 activity and cytochrome c in the cells.
Conclusion: These findings suggested that PDp has potential role as a neuroprotective and therapeutic
agent for combating human AD.